Longeveron Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
Longeveron reported significant advancements in Q3 2025, including the completion of enrollment in its pivotal HLHS clinical trial and a focused strategy to secure additional financing.
Key takeaways
- Completed enrollment for the ELPIS II pivotal Phase IIb clinical trial, with results expected in Q3 2026, paving the way for potential regulatory approval.
- Extended cash runway into late Q1 2026 through operational decisions and an at-the-market financing facility, with potential to raise up to $10.7 million if needed.
- Focus on bolstering BLA preparedness ahead of the ELPIS II data release, with adjusted timelines for full BLA filing anticipated in 2027.